{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Moxifloxacin+Treatment+D", "query": { "intervention": "Placebo for Moxifloxacin Treatment D" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Moxifloxacin+Treatment+D&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T09:32:20.105Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05878522", "title": "A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "sisunatovir", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2023-05-15", "completion_date": "2023-10-30", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05878522" }, { "nct_id": "NCT02152332", "title": "A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "JNJ-54861911-Therapeutic Dose", "type": "DRUG" }, { "name": "JNJ-54861911 - Supratherapeutic Dose", "type": "DRUG" }, { "name": "JNJ-54861911-Matched Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Matched Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2014-07", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-24", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152332" }, { "nct_id": "NCT00543062", "title": "Staccato Prochlorperazine Thorough QT/QTc", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cardiotoxicity" ], "interventions": [ { "name": "Inhaled placebo", "type": "DRUG" }, { "name": "Oral placebo", "type": "DRUG" }, { "name": "Inhaled prochlorperazine 5 mg", "type": "DRUG" }, { "name": "Inhaled prochlorperazine 10 mg", "type": "DRUG" }, { "name": "Oral moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexza Pharmaceuticals, Inc.", "sponsor_class": "UNKNOWN", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2007-10", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2019-03-11", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00543062" }, { "nct_id": "NCT05716854", "title": "Electrophysiological Effects of Potential QT Prolonging Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-induced QT Prolongation", "Pharmacokinetics", "Pharmacodynamics" ], "interventions": [ { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Pimozide", "type": "DRUG" }, { "name": "Placebo (Part 1)", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "Moxifloxacin and Cobicistat", "type": "DRUG" }, { "name": "Placebo (Part 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Food and Drug Administration (FDA)", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 44, "start_date": "2023-03-21", "completion_date": "2023-06-13", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05716854" }, { "nct_id": "NCT02785770", "title": "A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-04447943", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2016-06-29", "completion_date": "2016-10-20", "has_results": true, "last_update_posted_date": "2018-12-28", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02785770" }, { "nct_id": "NCT03808298", "title": "Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Balovaptan therapeutic dose Treatment A", "type": "DRUG" }, { "name": "Balovaptan supra-therapeutic dose Treatment B", "type": "DRUG" }, { "name": "Active control [moxifloxacin] on Day 2 Treatment C", "type": "DRUG" }, { "name": "Active control [Moxifloxacin] on Day 15 Treatment D", "type": "DRUG" }, { "name": "Placebo for Balovaptan Treatment C", "type": "DRUG" }, { "name": "Placebo for Balovaptan Treatment D", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment A", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment B", "type": "DRUG" }, { "name": "Moxifloxacin Treatment C", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment C", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment D", "type": "DRUG" }, { "name": "Moxifloxacin Treatment D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 57, "start_date": "2019-02-07", "completion_date": "2019-07-13", "has_results": true, "last_update_posted_date": "2020-07-24", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03808298" }, { "nct_id": "NCT04238195", "title": "A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "TQT Study" ], "interventions": [ { "name": "Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo", "type": "DRUG" }, { "name": "Moxifloxacin 400mg", "type": "DRUG" }, { "name": "Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)", "type": "OTHER" }, { "name": "Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Spero Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2020-01-19", "completion_date": "2020-02-26", "has_results": false, "last_update_posted_date": "2020-03-13", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04238195" }, { "nct_id": "NCT05192369", "title": "A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "CTP-543", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Concert Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 48, "start_date": "2022-01-04", "completion_date": "2022-01-28", "has_results": false, "last_update_posted_date": "2022-03-04", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05192369" }, { "nct_id": "NCT01353729", "title": "A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "600 mg zanamivir + moxifloxacin placebo", "type": "DRUG" }, { "name": "1200 mg zanamivir + moxifloxacin placebo", "type": "DRUG" }, { "name": "zanamivir placebo + moxifloxacin placebo", "type": "DRUG" }, { "name": "zanamivir placebo + 400 mg moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2011-05-19", "completion_date": "2011-08-02", "has_results": false, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01353729" }, { "nct_id": "NCT05995444", "title": "A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Epetraborole and matching placebo", "type": "DRUG" }, { "name": "Epetraborole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AN2 Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2023-06-05", "completion_date": "2023-08-03", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-09T09:32:20.105Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05995444" } ] }